Cerebrolysin
FPF-1070 — Porcine Brain-Derived Neuropeptide Mixture
What is Cerebrolysin?
Cerebrolysin is a standardized mixture of porcine brain-derived neuropeptides and amino acids produced through enzymatic hydrolysis of porcine brain proteins. It is approved in several European and Asian countries for treatment of Alzheimer's disease, stroke, and traumatic brain injury. It contains multiple growth factors including BDNF, NGF, CNTF, and GDNF in their peptide fragments.
Cerebrolysin delivers a broad array of neurotrophic peptide fragments that cross the blood-brain barrier and support neuronal survival, synaptic plasticity, and neurogenesis. Unlike single-target nootropics, it provides a multi-mechanism neurotrophic environment mimicking the brain's own growth factor milieu. It also reduces excitotoxicity, inhibits apoptosis, and has anti-amyloid properties relevant to Alzheimer's pathology.
Research Evidence
Multiple RCTs demonstrate significant cognitive improvement in Alzheimer's patients vs placebo. Meta-analyses support clinical benefit. Approved in EU and several Asian countries for this indication.
Phase 3 trials show improved motor and functional recovery in ischemic stroke patients when Cerebrolysin is administered within 24-48 hours of onset.
Clinical studies in traumatic brain injury show improved cognitive outcomes and neurological recovery with early Cerebrolysin administration.
Evidence grades: Gold = RCT human data · Silver = consistent animal/human data · Bronze = limited or preliminary
Dosing Protocols
Reconstitution Guide
This compound does not require reconstitution — it is available as a pre-mixed injectable or oral formulation.
Frequently Asked Questions
Is Cerebrolysin available in the US?
Not FDA approved in the United States. It is approved in Germany, Austria, Russia, China, South Korea, and many other countries. US residents typically access it through international pharmacies or during medical treatment abroad. It is not available through US compounding pharmacies.
How does Cerebrolysin compare to single nootropic peptides like Semax?
Cerebrolysin provides a broad multi-factor neurotrophic environment through dozens of peptide fragments. Single peptides like Semax target specific mechanisms (BDNF upregulation, dopaminergic modulation). Cerebrolysin is more clinically validated with Gold-level RCT data for Alzheimer's and stroke — something no single nootropic peptide can claim. For serious neurological indications, Cerebrolysin has the stronger evidence base.
References
- [1]Alvarez XA, Cacabelos R, Sampedro C, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three doses. Eur J Neurol. 2011;18(1):59-68.
- [2]Ladurner G, Kalvach P, Moessler H; Cerebrolysin Study Group. Neuroprotective treatment with Cerebrolysin in patients with acute stroke. J Neural Transm. 2005;112(3):415-428.
This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.
Share this article